Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.
Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.
复制标题
阿片类药物使用障碍药物对汉密尔顿抑郁评定量表影响的纵向研究。
DOI：
10.1016/j.jad.2021.10.018
复制
发表时间：
2022
影响因子：
6.6
通讯作者：
UbolratPiamjariyakul
中科院分区：
文献类型：
--
作者：
Wang,Kesheng;DiChiacchio,Toni;Fang,Wei;Lander,Laura;Feinberg,Judith;Xie,Changchun;Winstanley,ErinL;UbolratPiamjariyakul
目的在一项阿片类药物使用障碍（OUD）的随机临床试验中，评价汉密尔顿抑郁评定量表（HAM-D）评分对抑郁症的纵向治疗效果。方法对国家药物滥用研究所临床试验网络协议-0051的数据进行二次数据分析。570例OUD患者随机接受丁丙诺啡/纳洛酮（BUP-NX， N= 287）或缓释纳曲酮注射（XR-NTX， N= 283）。HAM-D评分在基线和随访至36周时完成。对对数变换后的HAM-D评分进行线性混合模型分析，对抑郁状态进行广义线性混合模型分析。结果与BUP-NX组相比，随机分配到XR-NTX组的受试者在第1周和第3周的HAM-D评分较高（p<0.05）。在治疗前4周，无终身重性抑郁障碍（MDD）患者的HAM-D评分和抑郁状态在治疗与就诊之间存在显著的相互作用。过去一年的可卡因使用与HAM-D评分和抑郁状态仅在没有重度抑郁症的个体中存在关联，而过去一年的大麻使用与HAM-D评分和抑郁状态仅在重度抑郁症个体中存在关联。过去一年的安非他明使用与HAM-D得分仅在没有重度抑郁症的个体中相关，然而，终生焦虑与HAM-D得分无关，与重度抑郁症无关。结论在处方XR-NTX时，特别是在治疗的第一个月，监测抑郁症状是必要的。筛查抑郁症和多种药物滥用可以帮助临床医生确定适当的治疗方法。
ObjectiveThis study aimed to evaluate the longitudinal treatment effect on depression measured by Hamilton Depression Rating Scale (HAM-D) score in a randomized clinical trial for the treatment of opioid use disorder (OUD).MethodsWe conducted a secondary data analysis of data from the National Institute on Drug Abuse's Clinical Trials Network Protocol-0051. Patients with OUD (N= 570) were randomized to receive buprenorphine/naloxone (BUP-NX,n= 287) or extended-release naltrexone injection (XR-NTX,n= 283). The HAM-D score was completed at baseline and follow-up visit up to 36 weeks. A linear mixed model analysis was performed for log transformed HAM-D score and a generalized linear mixed model analysis was conducted for depression status.ResultsCompared with BUP-NX, subjects randomized to XR-NTX had higher HAM-D scores at weeks 1 and 3 (p<0.05). There were significant interactions between treatment and visit on HAM-D score and depression status during the first four weeks of treatments in individuals without lifetime major depressive disorder (MDD). Past year cocaine use was associated with HAM-D score and depression status just in individuals without MDD, whereas past year cannabis use was associated with HAM-D score and depression status just in individuals with MDD. Past year amphetamine use was associated with HAM-D score just in individuals without MDD, however, lifetime anxiety was associated with HAM-D scores regardless of MDD.ConclusionWhen prescribing XR-NTX, particularly in the first month of treatment, it is essential to monitor for depressive symptoms. Screening for depression and multiple substance abuse may help clinicians identify appropriate treatment.
登录
查看更多内容
DOI：
10.1177/0269881118806297
发表时间：
2018-12
期刊：
Journal of psychopharmacology (Oxford, England)
影响因子：
--
作者：
Ot'alora G M;Grigsby J;Poulter B;Van Derveer JW 3rd;Giron SG;Jerome L;Feduccia AA;Hamilton S;Yazar-Klosinski B;Emerson A;Mithoefer MC;Doblin R
通讯作者：
Doblin R
影响因子：
7.8
作者：
Dean, AJ;Bell, J;Mattick, RP
通讯作者：
Mattick, RP
影响因子：
17.7
作者：
Fava, Maurizio;Memisoglu, Asli;Ehrich, Elliot
通讯作者：
Ehrich, Elliot
影响因子：
4.8
作者：
Ballard ED;Luckenbaugh DA;Richards EM;Walls TL;Brutsché NE;Ameli R;Niciu MJ;Vande Voort JL;Zarate CA Jr
通讯作者：
Zarate CA Jr
纳曲酮治疗会导致抑郁症吗？
影响因子：
4.3
作者：
A. Dean;J. Saunders;Rodger Jones;R. Young;J. Connor;B. Lawford
通讯作者：
B. Lawford